ACIP recommends meningitis B vaccine for high-risk groups
The US Advisory Committee on Immunization Practices (ACIP) today voted unanimously to recommend the use of meningococcal group B vaccines in high-risk groups, such as those with low immunity and college students threatened by outbreaks.
The recommendation comes in the wake of federal approval of two serogroup B vaccines in recent months—Wyeth's Trumenba last October and Novartis's Bexsero in January.